Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics
Work
Year: 2018
Type: article
Abstract: Doravirine is a novel nonnucleoside reverse transcriptase inhibitor in development for use with other antiretroviral therapies to treat human immunodeficiency virus type 1 (HIV-1) infection. Doravirin... more
Institutions Merck & Co., Inc., Rahway, NJ, USA (United States), Orlando Clinical Research Center, University of Miami, Florida International University
Cites: 27
Cited by: 24
Related to: 10
FWCI: 1.621
Citation percentile (by year/subfield): 87.82
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funders Merck, University of Miami